ROIV

Roivant Sciences Ltd. 10-Q Summary: Quarter Ended June 30, 2026

Business Context and Reporting Period

This summary covers Roivant Sciences Ltd.'s (Roivant) unaudited financial results for the three months ended June 30, 2026. Roivant operates as a biopharmaceutical company utilizing a "Vant" subsidiary structure to develop and commercialize medicines. The company focuses on product candidates including brepocitinib (Priovant), IMVT-1402 (Immunovant), and mosliciguat (Pulmovant).

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Increased by $80.7 million to $367.8 million, driven primarily by a $49.1 million increase in Research and Development (R&D) and a $31.5 million increase in General and Administrative (G&A) expenses.
• R&D Drivers: Higher program-specific costs for the anti-FcRn franchise ($44.8 million increase) and mosliciguat ($4.7 million increase). Personnel-related expenses rose due to $4.1 million in employee bonuses tied to the Moderna settlement.
• G&A Drivers: Increased by $31.5 million, largely due to $18.8 million in employee bonuses related to the Moderna settlement and $6.3 million in employer payroll taxes associated with equity awards.
• Investment Valuation: The company recorded a $36.6 million unrealized gain on investments (Arbutus and Datavant), compared to a $19.1 million unrealized loss in the prior year period.
• Interest Income: Decreased by $11.4 million to $36.9 million due to lower interest rates and reduced balances in interest-bearing accounts.

Guidance, Outlook, and Material Events

• Moderna Settlement: On March 3, 2026, Roivant's subsidiary Genevant and affiliate Arbutus reached a global settlement with Moderna regarding LNP patent infringement. A fixed payment of $950 million was received on July 8, 2026 (subsequent to quarter-end), with $771.6 million allocated to Genevant. A contingent payment of up to $1.3 billion remains possible depending on the outcome of an appeal regarding 28 U.S.C. § 1498.
• Pipeline Catalysts:
  • Brepocitinib: FDA decision expected in Q3 2026 for dermatomyositis; Phase 3 data for non-infectious uveitis expected in 2H 2026.
  • IMVT-1402: Topline data expected in 2H 2026 for cutaneous lupus erythematosus and difficult-to-treat rheumatoid arthritis.
  • Mosliciguat: Phase 2 topline data expected in 2H 2026 for pulmonary hypertension associated with interstitial lung disease.
• Liquidity: Management believes existing cash and marketable securities ($3.8 billion) are sufficient to fund operations for the foreseeable future. No immediate need for additional capital is anticipated.
• Share Repurchases: Approximately $681.7 million remains available under the current $1.0 billion repurchase program.

Investor Verification Checklist

• Moderna Contingent Payment: Verify the status of the Federal Circuit appeal regarding the § 1498 defense, as the $1.3 billion contingent payment depends on this outcome.
• Brepocitinib FDA Decision: Monitor the PDUFA date in Q3 2026 for dermatomyositis approval, a key near-term catalyst.
• Share-Based Compensation: Review the impact of the Senior Executive Compensation Program, which includes significant performance restricted stock units (PSUs) with remaining expense of $103.5 million to be recognized through June 2027.
• Noncontrolling Interests: Note that a significant portion of the net loss ($100.8 million) is attributable to noncontrolling interests, reflecting the ownership structure of subsidiaries like Immunovant and Genevant.
• Contractual Commitments: Confirm the $42.5 million accrual for non-cancelable costs related to the discontinued batoclimab program and the $22.8 million minimum commitment for IMVT-1402 manufacturing.